Tyra Biosciences Inc. recently presented the design and preclinical characterization of TYRA-200, an oral small-molecule FGFR1/2/3 tyrosine kinase inhibitor (TKI) that shows high potency against all common mutant forms of FGFR2 and holds potential for the treatment of cancers driven by FGFR2 alterations.

The FDA has granted orphan drug designation to Vanda Pharmaceuticals Inc.’s VGT-1849B, a selective peptide nucleic acid-based JAK2 inhibitor for the treatment of polycythemia vera (PV).

Tidewave Bio has completed an FDA Interact meeting that provided regulatory feedback as the company advances its lead program, TBC-1, toward IND-enabling studies. The company is developing a universal, off-the-shelf immunotherapy platform that is converted into a patient-specific precision medicine in real time using a tumor biopsy.

Two independent studies have linked neuronal injury, inside or outside the brain, to cancer progression and offer new biomarkers and strategies for prevention. While cerebral cancer cells damage axons and drive tumor development, in other types of cancer affecting other organs, nerve disruption caused by tumor proximity triggers inflammation and a suppressive environment that may also be associated with immunotherapy resistance.

Mitochondrial transfer is known to occur from the tumor microenvironment into cancer cells, but now, Swiss researchers have shown a possible precursor to this is that cancer cells smuggle their mitochondria into healthy connective tissue cells, prompting their reprogramming to cancer-associated fibroblasts.

Telix Pharmaceuticals Ltd. received an FDA complete response letter (CRL) a day after the Aug. 27 PDUFA date for its BLA for radiopharmaceutical renal cancer imaging agent, Zircaix (TLX250-CDx, 89Zr-DFO-girentuximab).